Literature DB >> 3895032

Treatment of progressive supranuclear palsy with tricyclic antidepressants.

G C Newman.   

Abstract

After a single patient with progressive supranuclear palsy (PSP) improved when given amitriptyline, we compared the effects of amitriptyline, desipramine, and placebo on the symptoms and signs of four patients with PSP in a double-blind, double-crossover manner. There was good correlation between the use of tricyclic agents and symptomatic improvement, although all patients remained disabled. Amitriptyline produced better overall improvement, whereas desipramine preferentially improved apraxia of eyelid opening.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3895032     DOI: 10.1212/wnl.35.8.1189

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

1.  Treatment of progressive supranuclear palsy with methysergide. A clinical study.

Authors:  G Di Trapani; P Stampatore; A La Cara; A Azzoni; M L Vaccario
Journal:  Ital J Neurol Sci       Date:  1991-04

Review 2.  Progressive supranuclear palsy: clinical features, pathophysiology and management.

Authors:  A Rajput; A H Rajput
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Current and future treatments in progressive supranuclear palsy.

Authors:  Irene van Balken; Irene Litvan
Journal:  Curr Treat Options Neurol       Date:  2006-05       Impact factor: 3.598

4.  Progressive Supranuclear Palsy.

Authors:  Lawrence I. Golbe
Journal:  Curr Treat Options Neurol       Date:  2001-11       Impact factor: 3.598

5.  Pure akinesia: an atypical manifestation of progressive supranuclear palsy.

Authors:  H Matsuo; H Takashima; M Kishikawa; I Kinoshita; M Mori; M Tsujihata; S Nagataki
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-05       Impact factor: 10.154

Review 6.  A Review of Treatment Options for Progressive Supranuclear Palsy.

Authors:  Maria Stamelou; Günter Höglinger
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

7.  [Atypical Parkinson syndromes].

Authors:  A Strzelczyk; J C Möller; M Stamelou; A Matusch; W H Oertel
Journal:  Nervenarzt       Date:  2008-10       Impact factor: 1.214

Review 8.  Four-Repeat Tauopathies: Current Management and Future Treatments.

Authors:  Lawren VandeVrede; Peter A Ljubenkov; Julio C Rojas; Ariane E Welch; Adam L Boxer
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

9.  Long-term follow-up of deep brain stimulation of peduncolopontine nucleus in progressive supranuclear palsy: Report of three cases.

Authors:  Domenico Servello; Edvin Zekaj; Christian Saleh; Claudia Menghetti; Mauro Porta
Journal:  Surg Neurol Int       Date:  2014-09-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.